GFP/Luc Reporter Cell Line - JIMT-1

JIMT-1 is a human breast cancer cell line established from a patient with metastatic HER2-positive breast carcinoma who exhibited intrinsic resistance to trastuzumab therapy. The cell line is widely recognized as a clinically relevant model for studying mechanisms of HER2-targeted therapy resistance and tumor progression in breast cancer. JIMT-1 cells overexpress HER2 while displaying molecular features associated with aggressive tumor behavior, enhanced invasiveness, and therapeutic refractoriness. Consequently, this cell line has been extensively utilized in investigations of drug resistance, oncogenic signaling, and the development of next-generation targeted therapies. The GFP/Luc Reporter Cell Line - JIMT-1 is generated through stable integration of green fluorescent protein (GFP) and firefly luciferase (Luc) reporter genes into the parental JIMT-1 cells. This dual-reporter system enables real-time fluorescence visualization and highly sensitive bioluminescence imaging while preserving the key biological and pharmacological characteristics of the original cell line.

The JIMT-1-GFP/Luc reporter cell line is widely employed in breast cancer research for evaluating tumor growth, metastatic behavior, and therapeutic response in both in vitro and in vivo settings. Luciferase expression allows non-invasive longitudinal monitoring of tumor burden and treatment efficacy through bioluminescence imaging in xenograft models, enabling dynamic assessment of disease progression over time. GFP expression facilitates visualization of cell proliferation, migration, invasion, and tissue localization in cultured cells and excised tumors. This model is particularly valuable for investigating resistance mechanisms to HER2-targeted therapies, including trastuzumab and other anti-HER2 agents, as well as for evaluating novel targeted drugs, antibody-drug conjugates, and combination treatment strategies. In addition, the dual-reporter platform supports studies of tumor microenvironment interactions, cancer stem cell-associated phenotypes, epithelial–mesenchymal transition, and signaling pathways involved in therapeutic resistance. With stable reporter expression and reliable imaging performance, the JIMT-1-GFP/Luc cell line serves as a robust platform for translational breast cancer research and preclinical drug development.